Click here to view the August 2021 edition of eNews

Hamburg-based Exit Games GmbH has entered into a strategic partnership with Skillz Inc.. As part of the strategic partnership, Skillz has acquired a minority interest in Exit Games in the amount of 50 million US dollars. A team of the international law firm Taylor Wessing, led by Hamburg-based partner Jens Wolf, advised Exit Games on all legal issues in connection with the transaction.

Exit Games is the developer of the well-known network and multiplayer engine Photon, which allows software developers to create and host synchronous real-time applications.

The international law firm Taylor Wessing, led by Frankfurt based M&A partner Stephan Doom and Phil Shepherd from London, provided comprehensive legal advice to the International Chemical Investors Group (ICIG) on the acquisition of the sulphuric acid production plant in Bilbao from INEOS Enterprises.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent (U.S. Patent No. 11,033,569) protecting the composition of matter of F-star’s SB 11285, a second generation STING agonist.

Cambridge’s Mission Therapeutics is to receive a milestone payment of $20 million from Wall Street-quoted AbbVie as part of a neurodegenerative disease collaboration.

Mission is a drug discovery and development company focused on targeting the ubiquitin pathway; the partners are progressing selected deubiquitylating enzyme (DUB) targets into the next phase of research. 

Cambridge, UK, 05 Aug 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc.

Cambridge, UK – 4 August 2021 – Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology to identify new disease indications with high unmet needs that could be treated by Ono’s proprietary assets.

London, UK, 04 August 2021: Closed Loop Medicine Ltd, a healthcare company focused on developing drug + digital combination products, the next generation of patient centric pharmaceutical products, reports positive regulatory clinical data for its insomnia drug, ahead of regulatory submission of its combination product CLM-IN01 for insomnia. 

SOMERSET, N.J., August 3, 2021 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.